University of California, San Francisco, CA, USA.
Cancer Cell. 2017 Jul 10;32(1):6-8. doi: 10.1016/j.ccell.2017.06.007.
Two papers published recently in the New England Journal of Medicine describe the utility of abiraterone acetate, an androgen biosynthesis inhibitor, in the early treatment of metastatic prostate cancer. In addition to establishing a new standard of care, these two articles pose a number of important questions for future investigation.
最近发表在《新英格兰医学杂志》上的两篇论文描述了雄激素生物合成抑制剂阿比特龙在转移性前列腺癌的早期治疗中的效用。这两篇文章除了确立了新的治疗标准外,还为未来的研究提出了一些重要问题。